Results 111 to 120 of about 10,843,123 (260)

Ectodomain shedding of the amyloid precursor protein: Cellular control mechanisms and novel modifiers [PDF]

open access: yes, 2006
Proteolytic cleavage in the ectodomain of the amyloid precursor protein (APP) is a key regulatory step in the generation of the Alzheimer's disease amyloid-beta (A beta) pepticle and occurs through two different protease activities termed alpha- and beta-
Lichtenthaler, Stefan F.
core   +1 more source

Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3

open access: yesAnnals of Neurology, EarlyView.
Repeat expansion disorders frequently involve peripheral neuropathy, yet mechanisms remain unclear. Using a spinocerebellar ataxia type 3 (SCA3) Knock‐In Atxn3Q300/Q6, we identify progressive sensorimotor deficits, peripheral nerve pathology, and dorsal root ganglia RNA splicing dysregulation.
Juan P. Mato   +7 more
wiley   +1 more source

White matter hyperintensities in Alzheimer's disease in the era of anti‐amyloid therapies

open access: yesAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
White matter hyperintensities (WMHs) are highly prevalent in Alzheimer's disease (AD) and arise from interacting vascular pathologies (including hypertensive small vessel disease and cerebral amyloid angiopathy) alongside inflammatory and ...
Antoine Garnier‐Crussard   +7 more
doaj   +1 more source

Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy [PDF]

open access: yes, 2009
Neurofibrillary tangles (NFTs) are associated with neuronal loss and correlate with cognitive impairment in Alzheimer disease, but how NFTs relate to neuronal death is not clear.
Carlson, George A   +4 more
core   +1 more source

Lecanemab over a two-year duration: Key insights from a regional specialty medical center

open access: yesThe Journal of Prevention of Alzheimer's Disease
Background and objectives: The anti-amyloid monoclonal antibody lecanemab (Leqembi®) treats patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD).
Lisa B.E. Shields   +14 more
doaj   +1 more source

Amyloid related imaging abnormalities (ARIA)

open access: yes, 2021
Frank Gaillard   +2 more
openaire   +1 more source

Multimodal Characterization of Glymphatic‐Related Magnetic Resonance Imaging Markers in Huntington's Disease: A Multi‐Cohort Retrospective Study

open access: yesAnnals of Neurology, EarlyView.
Objective To characterize magnetic resonance imaging (MRI)‐based glymphatic surrogates in Huntington's disease (HD) using MRI measures of perivascular diffusivity and structural perivascular alterations across multiple large cohorts. Methods We analyzed 2,731 MRI sessions from 880 participants across 3 large retrospective HD cohorts.
Alexia Solomon   +5 more
wiley   +1 more source

The Centiloid Scale in Amyloid PET Imaging: Current Role in Alzheimer’s Disease Diagnosis, Treatment Planning, and Monitoring During Anti-Amyloid Therapy: A Clinical Perspective

open access: yesDiagnostics
Amyloid positron emission tomography (PET) has become a critical tool in the diagnosis and treatment of Alzheimer’s disease (AD). The Centiloid (CL) scale, a tracer/scanner-independent, standardized quantification unit introduced in 2015, transforms ...
Houman Sotoudeh, Mohammadreza Alizadeh
doaj   +1 more source

Indole‐3‐Acetic Acid Protects Bovine Hepatocytes Against Palmitic Acid‐Induced Lipid Accumulation and ER Stress Through SIRT3

open access: yesAnimal Research and One Health, EarlyView.
Cows with ketosis during the perinatal period often experience damage to the liver, a core metabolic organ, thereby exacerbating the disease's inherent vicious cycle. This study indicates that serum 3‐IAA concentrations were reduced in ketotic cows and show a significant negative correlation with hepatic TG content.
Dandan Qi   +15 more
wiley   +1 more source

How many sites are enough? a novel, site-based power analysis method for real-world registry studies of anti-amyloid monoclonal antibodies

open access: yesJAR Life
Background: Real-world registries ALZ-NET (US) and AD-DMT (Japan) support safety surveillance of anti-amyloid antibodies. Conventional power calculations—dividing required patients by mean per-site caseload—can underestimate the number of centers needed ...
Kenichiro Sato   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy